<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Diabetes bone loss &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/diabetes-bone-loss/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 10 Jan 2026 22:20:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Diabetes bone loss &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>New Mitochondrial Inhibitor Reduces Diabetes-Related Bone Loss</title>
		<link>https://bioengineer.org/new-mitochondrial-inhibitor-reduces-diabetes-related-bone-loss/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 10 Jan 2026 22:19:51 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Diabetes bone loss]]></category>
		<category><![CDATA[İçeriğe uygun 5 etiket: `MSDC-0160]]></category>
		<category><![CDATA[Mitochondrial inhibitor]]></category>
		<category><![CDATA[Osteoclast differentiation]]></category>
		<category><![CDATA[Therapeutic development` **Açıklama:** 1. **MSDC-0160:** Çalışmanın ve tedavinin ana odağı olan bileşiği doğrudan belirtir. 2. **Mitochondrial inhibitor:** Bileşiğin temel etki me]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-mitochondrial-inhibitor-reduces-diabetes-related-bone-loss/</guid>

					<description><![CDATA[In an exciting development within the realm of metabolic health and bone biology, researchers have unveiled promising data on a novel therapeutic candidate, MSDC-0160. This clinical-stage compound operates as a mitochondrial pyruvate carrier inhibitor, targeting a critical pathway implicated in both glucose metabolism and bone loss specifically connected to type 2 diabetes (T2D). The study, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">315786</post-id>	</item>
	</channel>
</rss>
